Plain-English translation of NCT06922045 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Hemophilia research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing STSP-0601, a new medication given by injection, to help people with hemophilia A or B who have inhibitors—a complication where the body rejects standard clotting factor treatments. Researchers want to learn whether this medication can effectively stop bleeding episodes in these patients and whether it is safe to use. About 40 people will participate in this study.
People with hemophilia who develop inhibitors have very limited treatment options for stopping bleeding episodes, and existing therapies don't work well for them. This trial is exploring whether the new treatment can offer a better, safer option for controlling dangerous bleeding.
You likely qualify if…
You likely don't qualify if…
You would receive regular injections of the new medication over the course of the trial. The study team will monitor you closely to see how well the treatment controls your bleeding episodes and watch for any side effects. You'll need to keep track of any bleeding events and attend clinic visits so the researchers can check your health and response to the medication.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China